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Abstract
Context
Prader-Willi syndrome (PWS) is characterized by severe hyperphagia. Brain-derived neu-
rotrophic factor (BDNF) and leptin are reciprocally involved in energy homeostasis.
Objectives
To analyze the role of BDNF and leptin in satiety in genetic subtypes of PWS.
Design
Experimental study.
Setting
University hospital.
Subjects
90 adults: 30 PWS patients; 30 age-sex-BMI-matched obese controls; and 30 age-sex-
matched lean controls.
Interventions
Subjects ingested a liquid meal after fasting10 hours.
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Main Outcome Measures
Leptin and BDNF levels in plasma extracted before ingestion and 30’, 60’, and 120’ after
ingestion. Hunger, measured on a 100-point visual analogue scale before ingestion and 60’
and 120’ after ingestion.
Results
Fasting BDNF levels were lower in PWS than in controls (p = 0.05). Postprandially, PWS
patients showed only a truncated early peak in BDNF, and their BDNF levels at 60’ and 120’
were lower compared with lean controls (p<0.05). Leptin was higher in PWS patients than in
controls at all time points (p<0.001). PWS patients were hungrier than controls before and
after eating. The probability of being hungry was associated with baseline BDNF levels:
every 50-unit increment in BDNF decreased the odds of being hungry by 22% (OR: 0.78,
95%CI: 0.65–0.94). In uniparental disomy, the odds of being hungry decreased by 66% (OR:
0.34, 90%CI: 0.13–0.9). Postprandial leptin patterns did no differ among genetic subtypes.
Conclusions
Low baseline BDNF levels and lack of postprandial peak may contribute to persistent hun-
ger after meals. Uniparental disomy is the genetic subtype of PWS least affected by these
factors.
Introduction
Prader-Willi syndrome (PWS) is a genetic disorder caused by the lack of expression of the
paternally inherited genetic material located at 15q11-q13. This lack of expression is due to a
deletion (subtype I or II) of a region of the paternally inherited chromosome 15 in 65% to 75%
of cases, to maternal uniparental disomy (UPD) in 20% to 30% (both copies of chromosome 15
are inherited from the mother), or to an imprinting defect in 1% to 3% [1]. The clinical features
include neonatal hypotonia; intellectual disability; challenging behavior in response to changes
in routine; psychiatric features [2]; endocrine disorders, such as growth hormone deficiency or
hypogonadotropic hypogonadism; and the absence of satiety, which leads to early childhood
obesity [3] Behaviorally, individuals with deletion exhibit more severe problems than those
with UPD, including skin-picking and higher obsession for food [4]; by contrast, individuals
with UPD display higher levels of psychosis and social impairments [4].
Many studies aiming to elucidate the potential causes of hyperphagia in PWS have identi-
fied factors that might contribute to the absence of satiety in PWS, including high levels of the
orexigenic hormone ghrelin persisting in the postprandial state, low levels of pancreatic poly-
peptide, and a lack of the postprandial polypeptide YY peak [5–11]. Leptin, a hormone secreted
by adipose cells, regulates appetite by stimulating anorexigenic neurons and inhibiting orexi-
genic neurons in the arcuate nucleus of the hypothalamus. Obese individuals with or without
PWS have high leptin levels and leptin resistance [12–15]. However, some inconsistencies exist
across studies [16,17], and the role of these peptides remains unclear [17]. Although other mol-
ecules that could explain the lack of satiety in PWS have been sought, to date, our understand-
ing of this problem remains poor due to the complexity of the hunger-satiety circuitry ([8–20].
Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the development
and plasticity of the central nervous system [21]. BDNF is stored in platelets, from where it is
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released into the peripheral circulation [22]. Leptin and BDNF play reciprocal roles in inducing
satiety: leptin regulates BDNF expression, and BDNF plays a role in conveying the leptin
anorexigenic signal by regulating the formation or function of neuronal connections in brain
centers controlling energy balance [23]. BDNF is found in key brain regions involved in eating
behavior, energy homeostasis, and weight control [24], and it has been linked to obesity and
insulin resistance [25].
Animal models have demonstrated that BDNF haploinsufficiency leads to a reduction in
hypothalamic expression of BDNFmRNA that causes hyperphagia and obesity that could be
reversed by intracerebroventricular infusions of BDNF [26]. In humans, the loss of one copy of
the BDNF gene, caused by deletion of the region containing the gene in theWAGR (Wilms
tumor, aniridia, genitourinary anomalies, and intellectual disability) syndrome or by a chromo-
somal inversion, is associated with syndromic phenotypes linked to hyperphagia and obesity
[27,28]. Moreover, in humans, the BDNF p.Val66Met single nucleotide polymorphism has
been associated with obsessive-compulsive disorders [29], bipolar affective disorder [30], and
eating disorders such as anorexia nervosa or bulimia nervosa [31]. One study found obese chil-
dren had lower fasting BDNF than lean controls, and BDNF increased after lifestyle interven-
tion [32]. Another study found children with PWS had lower fasting BDNF than obese
controls [33]. To our knowledge, BDNF has not been studied in adult patients with PWS, and
postprandial BDNF levels have not been studied in obese patients with or without PWS.
Thus, we aimed to evaluate whether low BDNF levels could contribute to the pathogenesis
of hyperphagia and obesity in PWS. To this end, we measured fasting and postprandial BDNF
and leptin concentrations in plasma in adults with different genetic subtypes of PWS and com-
pared them with matched obese and healthy controls.
Subjects and Methods
Subjects
We studied 30 adults with PWS, 30 obese controls matched for age, sex, and BMI, and 30 lean
subjects matched for age and sex. All subjects were Caucasian and their weight was stable for at
least 3 months before inclusion in the study. PWS patients and obese controls were recruited
from the Endocrinologyand Nutrition Department, and lean subjects were hospital staff or
acquaintances that participated voluntarily. All subjects or their parents/guardians (in PWS
patients) provided written informed consent. The Institutional Ethics Committee of Corpora-
ció Sanitària Parc Taulí approved the protocol, and all investigations complied with the Hel-
sinki Declaration.
Five men with PWS were undergoing testosterone replacement for hypogonadism. Five
women with PWS were undergoing estrogen and progestagen therapy for hypogonadism; all
these were studied in the follicular phase. Although 14 subjects with PWS had been treated
with growth hormone until puberty, none were receiving growth hormone at the time of the
study. Seven subjects with PWS and one obese control had type 2 diabetes mellitus.
Intellectual disability in PWS subjects was mild in 77.4% and moderate in 22.6%.
Experimental methods
Before the study, PWS patients’ genetic diagnosis was established by methylation specific PCR
(MS-PCR) confirming the absence of the paternal allele at 15q11-q13, and deletion status was
established by fluorescence in situ hybridization. Deletions were classified as subtype (I or II)
using methylation-sensitive multiplex ligation-dependent probe amplification (MS-MLPA;
MRC-Holland; Amsterdam, The Netherlands). Microdeletions of the imprinting center were
also identified. In the absence of deletions, we analyzed multiple microsatellite markers
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distributed inside the 15q11-q13 region and along chromosome 15 in the probands and their
parents to distinguishmaternal UPD. When biparental inheritance was found, UPD was ruled
out, and PWS was attributed to an epigenetic imprinting defect.
For the baseline and postprandial study, subjects were admitted to the Unit at 8 a.m. after
an overnight fast of at least 10 hours. Anthropometrical parameters were determined by bio-
electrical impedance analysis (TANITA, body composition analyzer BC-418MA Biologica
Tecnologia Medica SL-BCN).
A catheter was inserted into the antecubital vein, and the line was maintained with saline
infusion. Blood samples were drawn for the fasting study. For the postprandial study, subjects
ingested a standard liquid meal (Resource 2.0, Nestle Lab, 1200 kcal, 43% carbohydrate, 39%
fat, 18% protein) and blood samples were drawn at 0, 30, 60 and 120 min. All samples were col-
lected on ice and spun at 4°C. Plasma was centrifuged and stored at 80°C until processed.
Assays were performed using commercially available methods. BDNF was quantified by an
enzyme-linked immunosorbent assay (ELISA) kit (Cat. No. CYT306,Millipore; Billerica,MA,
USA) following the manufacturers’ instructions. This kit’s intra-assay variation is ±3.7% and
its inter-assay variation is ±8.5% (125pg/mL). Leptin was determined using Luminex 200 and
the Human Metabolic Hormone Magnetic Bead Panel (HMHMAG-34K, Merck Millipore; Bil-
lerica,MA, USA) following the manufacturer’s instructions. This kit’s intra-assay variation is
±7% and its inter-assay variation is ±10% (184 pg/mL).
Before the meal and 60’ and 120’ after the meal, subjects quantified their hunger on a visual
analogue scale ranging from 0 to 100.
Statistical methods
To compare groups, we used ANOVA test for normally distributed variables and the Kruskal-
Wallis test for non-normally distributed variables.
We elaborated a general linear regression model with repeated measures for each peptide at
baseline that included the following covariates: sex, BMI, percentage of body fat, glucose, and
insulin.
We elaborated a logisticmodel for the binary indicator of being hungry after the meal.
Results are reported as odds ratios (OR) with corresponding 95% confidence intervals.
We used SAS system v9.2 (SAS Institute Inc., Cary, NC, USA) for all analyses.
Results
Fasting study
Table 1 reports subjects’ baseline characteristics. Lean subjects had lower values for BMI, waist
circumference, and percentage of body fat than the subjects in the other two groups.
Fasting glucose levels were lower in lean subjects than in PWS patients and obese controls.
There were no significant differences among the three groups in fasting insulin or insulin-resis-
tance determined by homeostatic model assessment (HOMA-IR-index). Fasting triglycerides
were higher in PWS subjects than in lean controls, although they were within the normal range
in all subjects (Table 1).
Plasma BDNF levels at fasting were lower in PWS patients than in obese and lean controls
(Χ2 = 5.785 p = 0.05). In fact, median BDNF for PWS was 113.7 pg/mL,more than 30% lower
than the median for the control groups (obese: 187.6 and lean: 158.2 pg/mL).Moreover, the
distribution of BDNF values in PWS subjects was more homogeneous and symmetric than in
the other two groups (Fig 1). CorrectingBDNF concentrations by the number of platelets did
not modify the results (data not shown).
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In the fasting study, leptin distributionwas asymmetric and PWS subjects showedmore var-
iability than obese and lean controls (Fig 2). The median of leptin was higher in PWS patients
than in the other groups (PWS: 35.3, obese: 18.5, and lean 4.41 ng/mL; Χ2 = 55.72, p<0.001).
As expected, in the baselinemodel for leptin controlling for sex, BMI, percentage of body
fat, glucose, and insulin, we found a significant effect for insulin (an increase of 100 μU/mL in
insulin increased leptin by 2 ng/mL; p = 0.033).
To evaluate the relationship between BDNF and leptin levels, we analyzed the BDNF/leptin
quotient, which is a relative measure of BDNF levels per unit of leptin. The BDNF/leptin quo-
tient was lowest in PWS patients (PWS: 3.9 (1.6–8.8) vs Obese: 11.1 (5.5–25.9) vs Lean: 35.3
(19.6–76.8); Χ2 = 44.79, p<0.001).
Postprandial study
Glucose, insulin, and triglyceride increased postprandially in all groups (Data not shown).
In lean subjects, postprandial BDNF peaked 60' after the liquid meal (p<0.05). However, in
subjects with PWS, there was only a truncated early BDNF peak, and BDNF levels were lower
than in lean controls 60' and 120' after the meal (estimatediff60 = 132.24; estimatediff120 =
99.94, p<0.05). In obese controls, postprandial BDNF pattern was intermediate between PWS
and lean controls, that is, similar to PWS patients with the early truncated peak, but without
significant differences at any time after the meal when compared to lean controls (Fig 3A).
Subjects with PWS had higher leptin levels than obese and lean controls during the post-
prandial study (estimatediff from 12.97–35.37, p<0.05 at all time points), without significant
changes in leptin concentrations over time in any groups (Fig 3B).
Relationship between hunger and levels of BDNF and leptin
Both before and after the meal, PWS subjects were hungrier than subjects in the other
groups. Hunger was scored from 0 to 100 as mentioned in the methods section. (Fasting:
PWS: 68.5±26.2, obese: 45.7±26.5, lean: 58.8±20.3, p<0.05; 60’ postprandial: PWS: 36±37.3,
obese: 8.3±11.4, lean: 6.5±12.9, p<0.05, 120’ postprandial: PWS: 43.7±37.9, obese: 9.83
±17.1, lean: 6.53±13.9, p<0.05).
Table 1. Baseline characteristics of all groups.
PWS (n = 30) Obese controls (n = 30) Lean controls (n = 30)
Sex (M/F) 15/15 15/15 15/15
Age (yr) 27.5±8.02 28.4±7.13 27.9±7.77
BMI (kg/m2) 32.4±8.14 33.7±6.88 22.1±2.05*$
Body fat (%) 37.0±8.39 35.7±9.70 20.3±7.23*$
Waist (cm) 105.0±18.37 105.3±15.14 78.3±7.43*$
Glucose (mg/dL) 94.1±22.03 98.20±32.08 86.7±6.64*$
Insulin (μU/mL) 333.7±218.5 493.19±213.7 304.8±134.7
HOMA-IR Index 1.69±0.84 2.94±1,57 1.69±0.77
Triglyceride (mg/dL) 89 (64–134) 83 (66–108) 61 (48–69)*
Platelets (x109/L) 256.2±69.0 256.9±61.3 230.2±46.4
p <0.05 vs
* PWS patients
$ obese patients.
All quantitative values are expressed as means±SD except for triglycerides, expressed as medians (interquartile range).
PWS: Prader-Willi Syndrome; BMI: body mass index; HOMA-IR: homeostatic model assessment insulin resistance.
doi:10.1371/journal.pone.0163468.t001
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In lean subjects, the postprandial BDNF peak at 60’ coincidedwith the lowest hunger score.
However, in PWS patients and in obese controls, the truncated early BDNF peak at 30’ did not
coincide with the lowest hunger score observed at 60’ (Fig 4A); moreover, postprandial leptin
levels over time were not associated with hunger scores in neither group (Fig 4B).
The logistic regression model found an association between postprandial hunger and base-
line BDNF levels in PWS subjects: for every 50 units increment in BDNF, the odds of being
hungry decreased by 22% (OR: 0.78, 95% CI: 0.65–0.94) and for every 10 units increase in base-
line BDNF/leptin quotient, the odds of being hungry decreased by 55% (OR: 0.44, 95% CI:
0.23–0.84)
Genetic subtype and BDNF, leptin, and hunger
The genetic tests confirmed 20 paternal deletions (7 subtype I and 13 subtype II), 7 UPDs, and
3 imprinting defects.
In the fasting state, BDNF levels were similar in all genetic subtypes. However, in the post-
prandial state, we observed small differences among subtypes in the pattern of BDNF levels
over time (Fig 5A). Subjects with type II deletion or imprinting defects had an early truncated
BDNF peak 30 minutes after the meal, followed by a decrease to baseline levels. However,
Fig 1. Plasma Brain-derived neurotrophic factor (BDNF) levels in subjects with Prader-Willi syndrome (PWS) and in obese
and lean control subjects. PWS subjects vs. obese and lean controls, P = 0.05.
doi:10.1371/journal.pone.0163468.g001
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subjects with type I deletion showed a delayed increase in BDNF levels. In subjects with UPD,
BDNF levels remained unchanged over time with a tendency to rise. No differences in post-
prandial leptin patterns were observed among genetic subtypes (Fig 5B).
In the fasting state, hunger scores, like fasting BDNF levels, did not differ among genetic
subtypes. However, after the meal, hunger scores differed with subtype (Fig 6). All subjects
with imprinting defects (100%), most subjects with type II deletions (76.9%), and slightly more
than half of those with type I deletions (57%) were still hungry 60 minutes after the meal. At
this time point, the hunger score had decreased significantly only in the UPD subgroup, where
only 28.6% of the subjects were still hungry (p = 0.05 between all groups). In UPD subjects,
every increase of 50 units in baseline BDNF, decreased the odds of being hungry by 66% (OR:
0.34, 90%CI: 0.13–0.9), whereas in the other genetic subtypes, baseline BDNF was not associ-
ated with any significant effect on the odds of being hungry.
Effects of previous treatment with growth hormone on BDNF, leptin, and
hunger score
BDNF levels, leptin levels, and hunger scores did not differ between patients who had been
treated with growth hormone before adulthood and those who had not (data not shown).
Fig 2. Plasma BDNF levels in subjects with Prader-Willi syndrome (PWS) and in obese and lean control subjects. P<0.01 PWS
subjects vs. obese and lean controls, obese controls vs. lean controls.
doi:10.1371/journal.pone.0163468.g002
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Fig 3. Postprandial BDNF (Brain-derived neurotrophic factor) (A) and leptin (B) levels in subjects with Prader-Willi syndrome
(PWS), in obese controls, and in lean controls. A peak in BDNF at 60 min was observed only in lean subjects (p<0.05 baseline vs 60
min in lean controls). Subjects with PWS had lower BDNF levels at 60 and 120 min than lean controls (p<0.05). Leptin levels within
groups did not change between baseline and postprandial measurements. PWS subjects had higher leptin levels than the other groups
at all time points (p<0.001).
doi:10.1371/journal.pone.0163468.g003
Postprandial BDNF in Prader-Willi Syndrome
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Fig 4. Fasting and postprandial plasma Brain-derived neurotrophic factor (BDNF) (A) and leptin (B) levels (circles) in the
three groups, overlaid with hunger score (stars) over time. Note that postprandial BDNF peak in lean controls coincides with the
lowest hunger score. PWS = Prader Willi Syndrome. Hunger was quantified on a visual analogue scale ranging from 0 to 100.
doi:10.1371/journal.pone.0163468.g004
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Fig 5. Baseline and postprandial Brain-derived neurotrophic factor (BDNF) (A) and leptin (B) levels in plasma by genetic
subtype. Note that uniparental disomy is the only genetic subtype with sustained BDNF levels.
doi:10.1371/journal.pone.0163468.g005
Postprandial BDNF in Prader-Willi Syndrome
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Discussion
To our knowledge, this is the first study to analyze fasting and postprandial plasma BDNF con-
centrations in adults with PWS. A previous study in children with PWS found low peripheral
BDNF (a reflectionof central BDNF) that may contribute to the lack of satiety in this syndrome
[33], and the present study extends these findings to adults. Moreover, we found that the post-
prandial peak in BDNF observed in lean controls at 60’ was absent in both PWS and obese sub-
jects and could contribute to their hyperphagia. Interestingly, postprandial patterns of BDNF
levels over time differed among genetic subtypes, and baseline BDNF levels seem to influence
the odds of being hungry after a meal.
The regulation of energy homeostasis is complex, and many central and peripheral signals
are involved in controlling hunger and satiety. BDNF is believed to act as a satiety signal down-
stream of leptin-melanocortin signaling [34]; however, no relationship between peripheral lep-
tin and plasma/serumBDNF concentrations has been demonstrated [33,35]. Interestingly, in
the present study the lowest BDNF/leptin quotient was seen in PWS subjects.Moreover, as was
previously found in children [36], leptin levels in our adult subjects with PWS were higher
than in lean controls, suggesting that the defect in energy homeostasis lies beyond leptin pro-
duction in the adipocyte, as if there were a resistance to the action of leptin. This defect could
affect transport across the blood-brain barrier or it could affect BDNF production downstream
of leptin-melanocortin signaling.
Leptin and BDNF are both necessary and act reciprocally to induce satiety [23]. Leptin can
stimulate the translation of long 3’UTR BDNFmRNA in neuronal dendrites through neuronal
Fig 6. Hunger score at fasting (circles) versus 60’ after the meal (stars) in the different genetic subtypes of Prader-Willi
syndrome subjects. P = 0.034 for uniparental disomy, nonsignificant for the rest. Hunger was quantified on a visual analogue scale
from 0 to 100.
doi:10.1371/journal.pone.0163468.g006
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activity. BDNF derived from this type of transcription is then required for leptin-induced neu-
ronal activity in several hypothalamic areas, where it probably regulates the formation, mainte-
nance, and function of neuronal connections in several cortical and hippocampal areas. When
BDNF signaling is compromised, neural circuits in these areas are dysfunctional, leading to
low local BDNF levels and therefore low peripheral concentrations (as a reflection of central
BDNF); consequently, adipocytes secrete more leptin, and as a result of leptin resistance, hun-
ger persists, leading to obesity. The present results are consistent with these observations since
adults with PWS had low fasting BDNF levels and no postprandial peak, independent of hun-
ger score. Moreover, higher fasting and postprandial plasma leptin concentrations in PWS sub-
jects and obese controls could reflect leptin resistance, suggesting that BDNF and leptin may
contribute, at least in part, to lack of satiety.
On the other hand, necdin, a signaling protein encoded by a gene located at 15q11-q12 that
is not expressed in PWS, modulates signals of BDNF by binding to its receptor. Both BDNF
and its receptor are coexpressed in hypothalamic nuclei associated with satiety, and the lack of
necdin promotes adipogenesis [37]. In the present study, the low peripheral BDNF levels in
PWS and baseline BDNF’s ability to predict postprandial hunger also support the hypothesis
of reduced central BDNF action leading to a lack of satiety and a predisposition to obesity.
Interestingly, obese subjects' BDNF pattern was similar to that of lean controls but without a
significant peak at 60’, making it intermediate between the patterns observed in PWS and lean
subjects. Thus, although postprandial hunger was similar in obese and lean controls, the lack of
BDNF peakmight predispose obese subjects to adipogenesis. These findings evidence the com-
plexity of the regulation of postprandial satiety circuits in obesity, whether syndromic or not.
The pattern of postprandial plasma BDNF levels differed among genetic subtypes of PWS.
In the UPD subtype, there was a sustained rise in BDNF over time, and a smaller proportion of
subjects were hungry after the meal. These findings agree with other authors’ observations that
UPD subjects have better self-control regarding food and more brain activity in the dorsolat-
eral prefrontal cortex and parahippocampal gyrus, regions involved in cognitive control over
decision-making (38). The less favorable postprandial BDNF pattern in subjects with type I
and II deletions or imprinting defects and the persistence of hunger after the meal in these sub-
types also make sense in light of the greater activity reported in these subtypes in brain regions
involved in the motivation to eat, such as prefrontal cortex and amygdala [38], as well as with
their higher tendency to overeat and to steal food, observed especially in patients with deletions
[4].
Whether growth hormone treatment decreases leptin levels is controversial [39,40]. We
found no differences in plasma leptin or BDNF concentrations in patients that had been treated
with growth hormone before adulthood and those who had not.
One limitation of this study is the small number of subjects in each subtype, so caution is
warranted in interpreting our results until they can be corroborated in further studies with
more patients. Furthermore, central BDNF would have been a more reliable marker than
peripheral BDNF, but determining central BDNF would have beenmore technically complex.
Moreover, as BDNF is stored peripherally in platelets, we corrected the results in function of
platelet counts, and the results remained unchanged. Likewise, corrections for body fat distri-
bution and HOMA_IR-index did not change the results.
In summary, our findings suggest that BDNF levels play a role in hyperphagia in subjects
with PWS; low baseline BDNF levels and a lack of postprandial BDNF peakmay be related to
the persistence of hunger after a meal. Further studies with more patients are needed to corrob-
orate the differences in postprandial BDNF patterns among the different genetic subtypes.
Postprandial BDNF in Prader-Willi Syndrome
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